These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

330 related articles for article (PubMed ID: 21574259)

  • 1. Diagnostic usefulness of EMA, IMP3, and GLUT-1 for the immunocytochemical distinction of malignant cells from reactive mesothelial cells in effusion cytology using cytospin preparations.
    Ikeda K; Tate G; Suzuki T; Kitamura T; Mitsuya T
    Diagn Cytopathol; 2011 Jun; 39(6):395-401. PubMed ID: 21574259
    [TBL] [Abstract][Full Text] [Related]  

  • 2. IMP3/L523S, a novel immunocytochemical marker that distinguishes benign and malignant cells: the expression profiles of IMP3/L523S in effusion cytology.
    Ikeda K; Tate G; Suzuki T; Kitamura T; Mitsuya T
    Hum Pathol; 2010 May; 41(5):745-50. PubMed ID: 20060157
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Practical utility of insulin-like growth factor II mRNA-binding protein 3, glucose transporter 1, and epithelial membrane antigen for distinguishing malignant mesotheliomas from benign mesothelial proliferations.
    Chang S; Oh MH; Ji SY; Han J; Kim TJ; Eom M; Kwon KY; Ha SY; Choi YD; Lee CH; Lee Y; Jung SH
    Pathol Int; 2014 Dec; 64(12):607-12. PubMed ID: 25376377
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Cytological differential diagnosis among adenocarcinoma, epithelial mesothelioma, and reactive mesothelial cells in serous effusions by immunocytochemistry.
    Su XY; Li GD; Liu WP; Xie B; Jiang YH
    Diagn Cytopathol; 2011 Dec; 39(12):900-8. PubMed ID: 20836004
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Distinguishing benign from malignant mesothelial cells in effusions by Glut-1, EMA, and Desmin expression: an evidence-based approach.
    Kuperman M; Florence RR; Pantanowitz L; Visintainer PF; Cibas ES; Otis CN
    Diagn Cytopathol; 2013 Feb; 41(2):131-40. PubMed ID: 23002041
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Utility of anti-L523S antibody in the diagnosis of benign and malignant serous effusions.
    Hanley KZ; Facik MS; Bourne PA; Yang Q; Spaulding BO; Bonfiglio TA; Xu H
    Cancer; 2008 Feb; 114(1):49-56. PubMed ID: 18098206
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The use of immunohistochemistry to distinguish reactive mesothelial cells from malignant mesothelioma in cytologic effusions.
    Hasteh F; Lin GY; Weidner N; Michael CW
    Cancer Cytopathol; 2010 Apr; 118(2):90-6. PubMed ID: 20209622
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Small orangiophilic squamous-like cells: an underrecognized and useful morphological feature for the diagnosis of malignant mesothelioma in pleural effusion cytology.
    Chen L; Caldero SG; Gmitro S; Smith ML; De Petris G; Zarka MA
    Cancer Cytopathol; 2014 Jan; 122(1):70-5. PubMed ID: 23983174
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Usefulness of EMA, GLUT-1, and XIAP for the cytologic diagnosis of malignant mesothelioma in body cavity fluids.
    Shen J; Pinkus GS; Deshpande V; Cibas ES
    Am J Clin Pathol; 2009 Apr; 131(4):516-23. PubMed ID: 19289587
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Malignant mesothelioma: immunohistochemistry and DNA ploidy analysis as methods to differentiate mesothelioma from benign reactive mesothelial cell proliferation and adenocarcinoma in pleural and peritoneal effusions.
    Friedman MT; Gentile P; Tarectecan A; Fuchs A
    Arch Pathol Lab Med; 1996 Oct; 120(10):959-66. PubMed ID: 12046609
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Immunocytochemical panel for distinguishing between carcinoma and reactive mesothelial cells in body cavity fluids.
    Politi E; Kandaraki C; Apostolopoulou C; Kyritsi T; Koutselini H
    Diagn Cytopathol; 2005 Mar; 32(3):151-5. PubMed ID: 15690338
    [TBL] [Abstract][Full Text] [Related]  

  • 12. IMP3 and GLUT-1 immunohistochemistry for distinguishing benign from malignant mesothelial proliferations.
    Lee AF; Gown AM; Churg A
    Am J Surg Pathol; 2013 Mar; 37(3):421-6. PubMed ID: 23108021
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Diagnostic utility of GLUT-1 expression in the cytologic evaluation of serous fluids.
    Afify A; Zhou H; Howell L; Paulino AF
    Acta Cytol; 2005; 49(6):621-6. PubMed ID: 16450901
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The significance of detecting glucose transporter 1 and calretinin in serous effusions to differentiate between carcinoma cells and reactive mesothelial cells.
    Lv M; Cha N; Zou YF; Leng JH; Hao YY; Wang S
    Diagn Cytopathol; 2021 Jul; 49(7):811-816. PubMed ID: 33818924
    [TBL] [Abstract][Full Text] [Related]  

  • 15. CK5/6 in effusions: no difference between mesothelioma and pulmonary and nonpulmonary adenocarcinoma.
    Dejmek A
    Acta Cytol; 2008; 52(5):579-83. PubMed ID: 18833821
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A fine decision tree consisted of CK5/6, IMP3 and TTF1 for cytological diagnosis among reactive mesothelial cells, metastatic adenocarcinoma of lung and non-lung origin in pleural effusion.
    Yan J; Wei Q; Jian W; Liu J; Tang H; Ge J; Zhou J; Zhao T
    Int J Clin Exp Pathol; 2014; 7(9):5810-8. PubMed ID: 25337222
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Oncofetal protein IMP3, a new diagnostic biomarker to distinguish malignant mesothelioma from reactive mesothelial proliferation.
    Shi M; Fraire AE; Chu P; Cornejo K; Woda BA; Dresser K; Rock KL; Jiang Z
    Am J Surg Pathol; 2011 Jun; 35(6):878-82. PubMed ID: 21566519
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Diagnostic value of BRCA1-associated protein-1, glucose transporter-1 and desmin expression in the discrimination between reactive mesothelial proliferation and malignant mesothelioma in tissues and effusions.
    Önder S; Özogul E; Koksal D; Sarinc Ulasli S; Firat P; Emri S
    Cytopathology; 2019 Nov; 30(6):592-600. PubMed ID: 31165505
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Comparative immunohistochemical analysis of IMP3, GLUT1, EMA, CD146, and desmin for distinguishing malignant mesothelioma from reactive mesothelial cells.
    Minato H; Kurose N; Fukushima M; Nojima T; Usuda K; Sagawa M; Sakuma T; Ooi A; Matsumoto I; Oda M; Arano Y; Shimizu J
    Am J Clin Pathol; 2014 Jan; 141(1):85-93. PubMed ID: 24343741
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Differentiation of mesothelioma from adenocarcinoma in serous effusions: the role of hyaluronic acid and CD44 localization.
    Afify AM; Stern R; Michael CW
    Diagn Cytopathol; 2005 Mar; 32(3):145-50. PubMed ID: 15690337
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 17.